Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NeuroOne Medical Technologies ( (NMTC) ) has provided an announcement.
On August 18, 2025, NeuroOne Medical Technologies Corporation announced it received FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System. This clearance allows the company to market the system for creating radiofrequency lesions to treat pain or for functional neurosurgical procedures, potentially enhancing its market position and offering new solutions for stakeholders.
The most recent analyst rating on (NMTC) stock is a Buy with a $1.45 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.
Spark’s Take on NMTC Stock
According to Spark, TipRanks’ AI Analyst, NMTC is a Neutral.
NeuroOne Medical Technologies shows strong revenue growth and promising corporate developments, but profitability challenges and valuation concerns weigh on the score. The company’s stable financial position and strategic initiatives provide a foundation for potential future growth.
To see Spark’s full report on NMTC stock, click here.
More about NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation operates in the medical technology industry, focusing on developing innovative solutions for neurological disorders. Its primary products include systems for neurostimulation and ablation, targeting the treatment of various neurological conditions.
Average Trading Volume: 197,166
Technical Sentiment Signal: Sell
Current Market Cap: $40.99M
Find detailed analytics on NMTC stock on TipRanks’ Stock Analysis page.